Mirion Technologies (MIR) Q2 2026: Backlog Climbs 40%, Locking in Nuclear Demand Visibility

2026-07-29 | By EarningsIQ Research

Mirion Technologies’ Q2 results underscore a step-change in nuclear demand visibility, with backlog surging 40% and large-scale order wins reinforcing momentum in both legacy and acquired businesses. The company’s positioning in the nuclear “supertrend” is translating into growing recurring revenue streams, while margin expansion and disciplined capital allocation signal execution strength. Management’s confidence in full-year guidance is underpinned by robust backlog coverage and accelerating second-half revenue expectations.

Summary

• Backlog Expansion: Large-scale nuclear orders drove a 40% increase in total backlog, anchoring revenue visibility.
• Margin Leverage Emerges: Favorable mix and pricing offset M&A dilution and inflation, expanding enterprise margins.
• Nuclear Supertrend Tailwind: Regulatory and policy shifts are fueling generational demand, with Mirion’s installed base yielding durable recurring revenue.

Business Overview

Mirion Technologies provides radiation detection, measurement, and monitoring solutions to the nuclear, defense, and medical industries. The company operates in two segments: Nuclear & Safety, which serves nuclear power, defense, and industrial markets, and Medical, which addresses radiation therapy quality assurance (RTQA), nuclear medicine, and dosimetry. Revenue is generated through a mix of hardware, software, and services, with a significant portion derived from recurring business tied to the global installed base of nuclear reactors and healthcare facilities.

Performance Analysis

Mirion delivered strong top-line growth, with total revenue up 20% year-over-year, driven primarily by acquisitions (notably Paragon) and organic growth in key end-markets. Organic revenue growth was modest at 1%, reflecting tough comps in medical and a flat performance in nuclear power, but management emphasized that this aligns with expectations and sets up a stronger second half.

Adjusted EBITDA rose 27.5%, with margin expansion of 150 basis points, reflecting improved product mix and pricing discipline that more than offset acquisition dilution and inflationary pressures. The company generated $49 million in adjusted free cash flow, its best first-half result since going public, aided by working capital discipline and lower cash taxes. Share repurchases continued, with $25 million deployed in Q2, reflecting opportunistic capital allocation.

• Order Momentum: Core orders grew 10%, with total orders (including M&A) up 40%, led by large nuclear and SMR (Small Modular Reactor) wins.
• Medical Segment Mixed: RTQA outperformed, but nuclear medicine and dosimetry faced hardware demand delays, prompting a downward revision in those specific outlooks.
• Backlog Quality: Legacy backlog (excluding acquisitions) increased 17%, with the legacy installed base up nearly 40% versus Q2 2025, demonstrating robust underlying demand.

Revenue visibility is high, with 81% of full-year revenue already covered by first-half results and backlog expected to convert in the second half, mirroring prior years’ coverage and supporting management’s maintained guidance.

Executive Commentary

Strategic Positioning

1. Nuclear Power “Supertrend” and Installed Base Recurrence

Mirion’s strategic bet on nuclear power is paying off, as regulatory and policy shifts in North America and abroad drive a generational build-out. The installed base—accounting for 80% of nuclear revenue—anchors recurring and repeat business, while new build and SMR opportunities provide incremental growth. Management expects global nuclear capacity to triple by 2050, and Mirion’s presence in 50 of 60 Chinese reactors and leadership in advanced reactor projects reinforce its competitive moat.

2. Order Pipeline and Large-Scale Wins

The company’s large opportunity pipeline is robust, with management claiming a “right to win” on all deals above $10 million. Q2 saw the capture of all large opportunities that transacted, and early Q3 wins added $50 million in large orders, offsetting a one-off Chinese project cancellation. The pipeline is replenishing, with SMR and new build activity accelerating, and management is increasingly bullish on the pace and scale of opportunity conversion.

3. Margin Expansion Through Operating Leverage and Procurement

Margin improvement is driven by operating leverage, procurement efficiency, and disciplined SG&A control. Management sees half or more of the targeted margin expansion to 30% by 2028 coming from top-line growth and cost discipline, with procurement and “self-help” initiatives (including AI-driven productivity) contributing additional points. Near-term restructuring is expected to deliver incremental margin benefit in 2027.

4. Capital Allocation and M&A Discipline

Mirion continues to prioritize M&A as a strategic lever, with a pipeline of complementary targets and a track record of 20 deals over the last decade. Share buybacks and deleveraging are also in focus, with leverage expected to fall to 2.5x by year-end absent further acquisitions. AI investment is material but measured, running at about $5 million annually and expected to grow in line with adoption and product development needs.

5. AI-Driven Product and Process Innovation

AI is being deployed across three pillars: accelerating product development cycles, driving internal efficiency (e.g., automating compliance and back-office processes), and enabling new AI-powered customer solutions. Early results include faster software releases and integrated QA platforms in the medical segment, with management viewing AI as a multi-year lever for both margin and competitive differentiation.

Key Considerations

Q2 showcased Mirion’s ability to capitalize on nuclear demand tailwinds, while navigating segment-specific headwinds and integrating recent acquisitions. The company’s execution on backlog conversion, margin discipline, and order capture will be critical for sustaining momentum through year-end and beyond.

Key Considerations:

• Backlog Conversion Pace: Timely execution on record backlog is essential, especially as Q4 requires a step-up in nuclear and safety segment revenue.
• Medical Segment Variability: Hardware demand delays in nuclear medicine and dosimetry are being offset by software growth, but visibility remains lower than in nuclear.
• China Market Exposure: Recent project cancellation highlights geopolitical and project-cycle risk, though recurring installed base revenue remains stable.
• Margin Path to 30%: Achieving management’s ambitious 2028 margin target will require sustained operating leverage, procurement gains, and successful integration of acquired businesses.
• Capital Allocation Flexibility: Ongoing M&A and AI investments must be balanced against deleveraging and shareholder returns.

Risks

Execution risk is elevated in the second half as Mirion must deliver on a step-up in organic growth and margin expansion, particularly in nuclear and safety. Geopolitical uncertainty (e.g., China project cancellations) could impact backlog quality, though management views such events as rare. Medical segment demand delays and lumpy new build revenue introduce variability, while aggressive margin targets may face headwinds from integration and inflation. Regulatory or policy shifts could also alter the nuclear demand trajectory.

Forward Outlook

For Q3 2026, Mirion guided to:

• High single-digit consolidated organic revenue growth
• Adjusted EBITDA margin expansion year-over-year

For full-year 2026, management maintained guidance:

• Organic revenue growth of 7.5% to 11.2% in the second half
• Adjusted EBITDA margins of 27% to 29% in the second half
• Second-half adjusted free cash flow of $95 to $115 million

Management highlighted several factors that support this outlook:

• 81% of full-year revenue is already covered by backlog and first-half results, consistent with prior years
• Large opportunity pipeline and recent order wins reinforce visibility, though timing risk remains

Takeaways

• Backlog and Order Strength: Mirion’s Q2 backlog growth and order capture reinforce its positioning as a key beneficiary of the nuclear power build-out, driving recurring revenue and near-term visibility.
• Margin Expansion and Leverage: Operating leverage, procurement, and AI-driven initiatives are delivering margin gains, but achieving the 30% margin target by 2028 will require sustained execution as M&A integration continues.
• Pipeline, Policy, and Execution Watch: Investors should monitor the pace of backlog conversion, the impact of regulatory/policy support, and the company’s ability to navigate medical segment variability and geopolitical risk.

Conclusion

Mirion’s Q2 results highlight a business at the intersection of a global nuclear resurgence and disciplined operational execution. Backlog strength, margin expansion, and a replenishing opportunity pipeline underpin management’s confidence in delivering accelerated growth and profitability in the second half and beyond.

Industry Read-Through

Mirion’s results and commentary reinforce the nuclear sector’s emergence as a multi-decade growth story, with policy momentum, regulatory clarity, and financing support converging to drive both legacy and new-build demand. Suppliers with installed base exposure and recurring service models are poised to benefit from this generational shift, while those reliant on hardware or new build cycles may face greater volatility. AI-driven productivity and compliance enhancements are becoming table stakes for industry players seeking to scale efficiently. Geopolitical risk in China and other markets remains a watchpoint, but the underlying trend is toward expanding global nuclear capacity and durable supplier revenue streams.

MIR Industrials Nuclear Recurring Revenue Backlog Margin Expansion AI M&A